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Abstract General practitioners are key stakeholders in
good prescribing practices. More than half of patients have
at least one unintended medication discrepancy upon hos-
pital admission, some of which have the potential to cause
severe discomfort or clinical deterioration. We report a
case of a drug mistakenly administered to a 66-year-old
man with cirrhosis and chronic alcoholism. Based on his
regular prescription, he received 1 g/day of valproate
during a hospitalization for cardiac valve surgery. This
anticonvulsant was initially prescribed by his general
practitioner for his epileptic dog and has been added to his
own prescription to be covered by the French national
health insurance. The aim of this article is to emphasize
that general practitioners, physicians, and pharmacists have
a major role to play in preventing the diversion of pre-
scription drugs and limiting the risk of adverse drug events.
Key Points
Prescription drug diversion is a serious public health
problem that can lead to severe adverse
consequences.
Medication reconciliation is a strategy requiring a
complete review of all the medication taken by a
patient during his/her hospitalization (admission,
transfer, and discharge).
Physicians and pharmacists have a major role to play
in preventing the diversion of prescription drugs and
can be helped by medication reconciliation.
Introduction
The diversion of prescription drugs is a serious public
health problem that can lead to severe adverse conse-
quences such as overdose, admission to an emergency
department, or death. The most affected drugs are opioid
analgesics (hydrocodone, oxycodone), central nervous
system depressants (alprazolam, diazepam), or stimulants
(amphetamine) [1]. Lifestyle and prescription drug diver-
sion can increase the risk of adverse drug events [2].
Because of a prescription given to the physician at
admission, a 66-year-old man referred for cardiac valve
surgery received oral valproate during his hospitalization.
This drug was not initially prescribed for him but for his
epileptic dog, in accordance with his general practitioner,
to benefit from the reimbursement of the drug by the
French national health insurance.
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Case Report
A 66-year-old man hospitalized for cardiac valve surgery
was admitted to the cardiology department for acute heart
failure. His past medical history included alcoholic cir-
rhosis (Child A6) complicated by esophageal varices for
10 years, paroxysmal atrial fibrillation for 4 years, a mildly
reduced kidney function (estimated glomerular filtration
rate: 60–89 mL/min/1.73 m2) and 1 year prior, he had a
mitral and aortic valve endocarditis caused by Staphylo-
coccus epidermidis (successfully treated with intravenous
vancomycin, gentamicin, and cloxacillin). His regular
prescription medication at admission included isosorbide
mononitrate (24 mg/day), valproate (1 g/day), inhaled
beclomethasone (400 lg/day), furosemide (125 mg/day),
and vitamin supplements. Blood biochemistry evaluations
revealed the following: increases in the plasma potassium
level to 6.1 mmol/L (reference range 3.6–4.8 mmol/L) and
troponin I level to 0.09 ng/mL (reference range\0.04 ng/
mL). Plasma creatinine level was 117.6 lmol/L (reference
range 40–100 lmol/L) with a moderate renal impairment
(clearance calculated by the Modification of Diet in Renal
Disease equation: 54 mL/min/1.73 m2). Observations
revealed a heart rate of 145 beats per minute, a blood
pressure of 130/81 mmHg, and a normal oxygen saturation
level of 98% with supplemental oxygen therapy (nasal
cannula, 2 L/min). An electrocardiogram showed a heart
rate of 154 beats per minute and atrial fibrillation. Aus-
cultation revealed crepitant rales with murmurs, hepato-
jugular reflux, and edema in the lower extremities. A chest
X-ray showed signs of cardiogenic pulmonary edema such
as cardiomegaly, unilateral pleural effusion on the right
side, and peripheral edema. The patient showed a good
response to intravenous furosemide. After an improvement
in the initial heart failure, the valve surgery was postponed
because of a progressive increase in baseline liver enzymes
level without fever. At day 3, the patient confessed to
physicians an excessive drinking behavior (more than 1 L
of beer every day) and a daily acetaminophen consumption
(8 g every day): valproate and acetaminophen were stop-
ped. Blood toxicological analysis collected on the fourth
day showed a valproate concentration of 42.8 mg/L (ther-
apeutic range 40–100 mg/L) followed by a gradual
decrease, and an acetaminophen concentration under the
lower limit of quantification (Fig. 1, day 4). Liver function
analysis showed that the level of gamma-glutamyl
transpeptidase was increased [peak plasma level on the
fourth day at 386 U/L (reference range 5–55 U/L)], as well
as the levels of alanine aminotransferase and aspartate
aminotransferase [peak plasma levels on the fifth day at
3997 and 3452 U/L, respectively (reference range 5–45
U/L)]. The levels of total bilirubin and conjugated bilirubin
were increased with a peak plasma level on the fifth day at
44 (reference range 1–17 lmol/L) and 16 lmol/L (refer-
ence range \3 lmol/L), respectively. Alkaline phos-
phatase, prothrombin time, and international normalized
ratio were within normal limits. No ammonia, brain natri-
uretic peptide, glutathione level analysis, and liver biopsy
were performed. Abdominal ultrasound showed a cirrhotic
liver without bile duct obstruction. Hepatic veins were also
normal. Viral infections were ruled out by blood exami-
nations (viral hepatitis A, B, C, D, and E; human immun-
odeficiency and herpesviridae viruses). Intravenous
administration of N-acetylcysteine started on day 5 (Fig. 1)
and was associated with a decrease in liver enzymes that
gradually returned to normal values and then were com-
pletely back to normal 1 month later. The patient admitted
that valproate was not originally prescribed for him but for
his dog to benefit from the reimbursement of this drug by
the French national health insurances (veterinary drugs are
indeed at the entire charge of the dog owner) and unfor-
tunately the valproate was initiated upon his admission
because it was noted as being one of the patient’s regular
prescription drugs. Investigations revealed that this practice
began 6 months previously.
Discussion
Drug diversion is an illegal distribution, an abuse of pre-
scription drugs, or a use for purposes not intended by the
prescriber. It manifests itself through various forms such as
illegal Internet pharmacies, prescription forgery doctor
shopping, or illicit prescribing by physicians [3]. The
results from the 2012 National Survey on Drug Use and
Health present the prescription drug abuse as a new epi-
demic and people are unaware that it causes harms, deaths,
and economic costs [4]. Anabolic steroids, depressants,
stimulants, hallucinogens, and opioids have a high poten-
tial for diversion [5]. In USA, the non-medical use of
prescription drugs concerns 20% of the population (52
million people aged 12 years and older) [6]. To thwart drug
diversion, physicians are helped by the development of
new tools before prescribing, such as ‘prescription drug
monitoring programs’, even if some practitioners disagree
with the idea of using it (usability, dissatisfaction, erosion
of physician autonomy) [7]. Community pharmacists also
use educational supports and data-sharing projects for the
management of patients suspected to be at high risk for
drug diversion [8, 9]. In hospitals, pharmacists are
responsible for the safe use of medications by reducing the
risk of adverse events through medication reconciliation.
They try to obtain the most accurate list of patients’ current
medicines to ensure that medications being added,
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changed, or discontinued during hospitalization are cau-
tiously evaluated. Hospital pharmacists significantly
reduced the number of medication errors (including errors
of high and extreme risk) [10, 11]. The aim is to reduce
medication discrepancies and to prevent future events
related to drug omissions (medication taken by the patient
without any mention in the medical record), drug com-
missions (medication present in the medical record but not
taken by the patient), drug duplications, dosing errors, and
drug–drug interactions [12]. At admission, our patient
received by error a non-indicated drug without having
benefited from medication reconciliation. Since this event,
we extended medication reconciliation to cardiology and
nephrology care units. Unfortunately, we have no scientific
data on the diversion of prescription drugs in France, but it
seems not to be a common practice, unlike opioid diversion
[13, 14]. Limiting the diversion of prescription drugs
requires a coordinated approach between each member of
the health system: pharmacists, physicians, and general
practitioners, all supported by fraud control. This coordi-
nated approach includes equal access to electronic medical
records and the provision of additional continuing educa-
tion to healthcare professionals.
Conclusion
This case report highlights the imperative need to strictly
control indications of home drugs administered during
hospitalization and the damaging consequences of the
inappropriate use of reimbursement systems. A study found
that 53.6% of patients had at least one unintended medi-
cation discrepancy upon admission, some of which had the
potential to cause severe discomfort or clinical deteriora-
tion [15]. Moreover, these controls could limit adverse
drug events, which represent a significant financial burden
to healthcare with a US$887 million estimated cost in 2006
in USA [16]. General practitioners, physicians, and phar-
macists play a major role in this context. They could be
helped by the development of medical conciliation at
patient hospital admission or discharge and by new
healthcare delivery processes or tools [17, 18].
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levels are represented on the left
axis, the other parameters on the
right axis. Markers indicate the
beginning of valproate therapy
(filled triangle) and valproate
drug monitoring (shaded
triangle)
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